Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants
I'm LongbridgeAI, I can summarize articles.Zentalis Pharmaceuticals has launched an underwritten public offering of common stock, allowing investors to purchase pre-funded warrants. The underwriters hold a 30-day option to buy up to 15% additional shares. Proceeds will fund clinical trials, regulatory filings, manufacturing, and working capital. TD Cowen, Guggenheim Securities, and Oppenheimer serve as joint bookrunners.
- Zentalis launched a proposed underwritten public offering of common stock. * Some investors can choose pre-funded warrants to buy common shares in lieu of stock. * Underwriters hold a 30-day option to purchase up to 15% additional shares on the same terms. * Proceeds earmarked for clinical trials, preclinical work, regulatory filings, manufacturing, companion diagnostic development, pre-commercial activities, capital spending, working capital. * TD Cowen, Guggenheim Securities, Oppenheimer are joint bookrunners. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809901) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)